References
- Hatemi G, Seyahi E, Fresko I, Hamuryudan V. Behçet’s syndrome: a critical digest of the recent literature. Clin. Exp. Rheumatol. 30(3 Suppl. 72), S80–S89 (2012).
- Emmi L. Behçet’s Syndrome From Pathogenesis to Treatment (2014 Edition). Series: Rare Diseases of the Immune System. Springer, NY, USA (2013).
- Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behçet’s disease: an update. Curr. Opin. Rheumatol. 23(1), 24–31 (2011).
- Seyahi E, Yurdakul S. Behçet’s syndrome and thrombosis. Mediterr. J. Hematol. Infect. Dis. 3(1), e2011026 (2011).
- Emad Y, Ragab Y, Shawki Ael-H, Gheita T, El-Marakbi A, Salama MH. Hughes-Stovin syndrome: is it incomplete Behçet’s? Report of two cases and review of the literature. Clin. Rheumatol. 26(11), 1993–1996 (2007).
- Bono W, Filali-Ansary N, Mohattane A et al. Cardiac and pulmonary artery manifestations during disease. Rev. Med. Intern. 21(10), 905–907 (2000).
- La Regina M, Gasparyan AY, Orlandini F, Prisco D. Behçet’s disease as a model of venous thrombosis. Open Cardiovasc. Med. J. 4, 71–77 (2010).
- Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr. Opin. Rheumatol. 25(1), 19–25 (2013).
- Onur E, Kabaroğlu C, Inanir I et al. Oxidative stress impairs endothelial nitric oxide levels in Behçet’s disease. Cutan. Ocul. Toxicol. 30, 217–220 (2011).
- Turkoz Y, Evereklioglu C, Ozkiriş A et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behçet’s syndrome. Mediators Inflamm. 2005, 237–241 (2005).
- La Regina M, Orlandini F, Prisco D, Dentali F. Homocysteine in vascular Behçet disease: a meta-analysis. Arterioscler. Thromb. Vasc. Biol. 30(10), 2067–2074 (2010).
- Chambers JC, Haskard DO, Kooner JS et al. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. J. Am. Coll. Cardiol. 37(2), 517–520 (2001).
- Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behçet disease. Ann. Rheum. Dis. 67, 1656–1662 (2008).
- Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12(2), 147–168 (2013).
- Köse O. Development of immunopathogenesis strategies to treat Behçet’s disease. Patholog. Res. Int. 2012, 261989 (2012).
- Perra D, Alba MA, Callejas JL et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford) 51, 1825–1831 (2012).